NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has formed a six-member advisory board of distinguished neurosurgeons to aid in the development of its radio frequency ablation electrode. This technology aims to record and ablate brain tissue associated with seizure activity, enhancing surgical procedures for neurological disorders. CEO Dave Rosa emphasized the board's vital role in expediting technology that could improve patient outcomes and reduce costs. NeuroOne's Evo technology gained FDA clearance in November 2019, and the partnership with Zimmer Biomet offers exclusive distribution rights and potential milestone payments.
- Formation of a six-member advisory board of leading neurosurgeons enhances expertise and credibility.
- Development of a technology expected to improve surgical outcomes and reduce costs for patients and physicians.
- Existing partnership with Zimmer Biomet may lead to milestone payments and broader market acceptance.
- Risks associated with the commercialization of the ablation technology and its readiness for market.
- Potential uncertainties related to regulatory approvals and clinical trial outcomes.
- Dependence on partnerships for successful product commercialization may introduce vulnerabilities.
EDEN PRAIRIE, Minn., June 2, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the formation of a six member advisory board of leading neurosurgeons to assist in the completion of development of a radio frequency ablation electrode intended to record and ablate brain tissue linked to causing seizure activity.
The six members that have been appointed to the advisory board are as follows:
- Dr. Daniel Couture, Wake Forest Baptist Health
- Dr. Gerald Grant, Stanford University Medical Center
- Dr. Bob Gross, Emory University
- Dr. Zachary Levine, Holy Cross Health, George Washington University
- Dr. Guy McKhann, New York Presbyterian Hospital, Columbia University
- Dr. Jamie Van Gompel, Mayo Clinic
NeuroOne CEO Dave Rosa says, "We are honored to have an opportunity to partner with such distinguished neurosurgeons who I believe will be extremely helpful in accelerating our ablation electrode technology program. Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure. The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology."
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the development of the Company's ablation electrode technology program, the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology, what the future may hold for electrical stimulation and NeuroOne's potential role, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
"Caution: Federal law restricts this device to sale by or on the order of a physician"
View original content to download multimedia:http://www.prnewswire.com/news-releases/neuroone-introduces-advisory-board-for-ablation-electrode-technology-that-records-and-ablates-brain-tissue-linked-to-seizure-activity-301302094.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
What is the purpose of NeuroOne's new advisory board?
Who are the members of the advisory board for NeuroOne?
What technology is NeuroOne developing?
What are the expected benefits of the new technology being developed by NeuroOne?
How does NeuroOne's partnership with Zimmer Biomet impact its business?
